##{"id":82627,"date":"2019-09-18T09:07:32","date_gmt":"2019-09-17T23:07:32","guid":{"rendered":"https:\/\/www.fnarena.com\/?p=82627"},"modified":"2019-09-18T09:07:32","modified_gmt":"2019-09-17T23:07:32","slug":"research-interview-bob-proulx-ceo-imagion-biosystems","status":"publish","type":"post","link":"https:\/\/staging.fnarena.com\/index.php\/2019\/09\/18\/research-interview-bob-proulx-ceo-imagion-biosystems\/","title":{"rendered":"RESEARCH: Interview\u00a0Bob Proulx, CEO Imagion Biosystems"},"content":{"rendered":"<p><em>Interview&nbsp;with Bob Proulx, CEO Imagion Biosystems<\/em><\/p>\n<p>By Pitt Street Research<\/p>\n<p><!--StartFragment --><u><strong>Imagion Biosystems: Breakthrough imaging technology<\/strong><\/u><br \/>\n&nbsp;<br \/>\nWe spoke with Bob Proulx, CEO Imagion Biosystems ((IBX)), about Imagion&#039;s revolutionary MagSense imaging technology, which is potentially orders of magnitude more effective than CT and MRI at detecting cancer.<\/p>\n<p>MagSense was granted Breakthrough Device status by the FDA in June 2019 and is currently being prepared for its first clinical study, potentially in Her2-positive breast cancer.<\/p>\n<p>Watch the whole interview through the link below.<\/p>\n<p><a href=\"https:\/\/www.pittstreetresearch.com\/imagion-biosystems\">https:\/\/www.pittstreetresearch.com\/imagion-biosystems<\/a><\/p>\n<p>Last week the video&nbsp;above was released by Pitt Street Research for which FNArena&nbsp;is a partner in distribution.<\/p>\n<p><em>Find out why FNArena subscribers like the service so much: &quot;<a href=\"http:\/\/www.fnarena.com\/index4.cfm?type=dsp_newsitem&amp;n=29EB960D-9DFF-C00E-7F6B464E5D52E250\">Your Feedback (Thank You)<\/a>&quot; &#8211; Warning this story contains unashamedly positive feedback on the service provided.<\/em><\/p>\n<p><em>FNArena&nbsp;is proud about its track record and past achievements: <a href=\"https:\/\/www.fnarena.com\/index.php\/2018\/10\/03\/rudis-view-ten-years-on-the-world-is-still-turning\/\">Ten Years On<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pitt Street Research interviewed Bob Proulx, CEO Imagion Biosystems<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/82627"}],"collection":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/comments?post=82627"}],"version-history":[{"count":0,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/82627\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/media?parent=82627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/categories?post=82627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/tags?post=82627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}